Jazz Pharmaceutical to Acquire Cavion for the Expansion of its Sleep and Neurology Portfolio
Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
Shots:
- Jazz acquires Cavion, in all stock transaction making total deal value $312.5M. Cavion to receive $52.5M up front, ~$260M milestones based on certain clinical, regulatory and commercial activities
- The acquisition will broaden Jazz’s portfolio of sleep and neurological disorders and with the addition of Cavion’s CX-8998 it will further lead to expansion into movement disorders
- CX-8998 is a modulator of t-type calcium channels and is currently evaluated in P-II trial vs PBO in patients with essential tremor with its expected onset in 2020
Click here to read full press release/ article | Ref: Jazz Pharmaceuticals | Image: Behnace